Clinical characteristics and surgical outcomes of low-grade epilepsy-associated brain tumors
View abstract on PubMed
Summary
This summary is machine-generated.Complete resection and negative electroencephalography (EEG) are key to seizure freedom after low-grade epilepsy-associated brain tumor (LEAT) surgery. Poor seizure outcomes are linked to partial resection and persistent epileptiform discharges. This study identifies critical factors for improving LEAT treatment success.
Area Of Science
- Neurosurgery
- Epileptology
- Neuropathology
Background
- Low-grade epilepsy-associated brain tumors (LEATs) are a common cause of epilepsy, with a low malignant potential.
- Treatment for LEATs prioritizes seizure control over oncological outcomes due to good overall survival rates.
Purpose Of The Study
- To identify risk factors influencing seizure outcomes in patients with LEATs following resective surgery.
- To evaluate the effectiveness of various surgical and diagnostic parameters in predicting seizure control.
Main Methods
- Retrospective analysis of 111 patients with LEATs undergoing resective surgery across three epilepsy centers.
- Assessment of demographic, clinical, neurophysiological, and neuropathological data.
- Application of Synthetic Minority Oversampling Technique (SMOTE) and Gaussian Naïve Bayes (GNB) algorithms for outcome prediction.
Main Results
- Seizure freedom rates were 91.0% at 1 year, 87.5% at 2 years, and 79.1% at 5 years.
- Partial resection, positive intraoperative electrocorticography (ECoG), and postoperative scalp electroencephalography (EEG) were associated with poorer seizure outcomes.
- The GNB-SMOTE model demonstrated high predictive accuracy for seizure outcomes at 1, 2, and 5 years.
Conclusions
- Partial resection and persistent epileptiform discharges (indicated by ECoG/EEG) are significant predictors of poor seizure outcomes.
- Intraoperative ECoG is valuable for optimizing seizure control strategies.
- A multivariate correlation analysis model based on GNB effectively predicts seizure outcomes in LEAT patients.

